224 related articles for article (PubMed ID: 18695872)
1. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
Pantaleo MA; Nannini M; Lopci E; Castellucci P; Maleddu A; Lodi F; Nanni C; Allegri V; Astorino M; Brandi G; Di Battista M; Boschi S; Fanti S; Biasco G
Int J Oncol; 2008 Sep; 33(3):443-52. PubMed ID: 18695872
[TBL] [Abstract][Full Text] [Related]
2. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
5. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Kanazu M; Maruyama K; Ando M; Asami K; Ishii M; Uehira K; Minomo S; Matsuda Y; Kawaguchi T; Atagi S; Ogawa Y; Kusunoki Y; Takada M; Kubo A
Clin Lung Cancer; 2014 May; 15(3):182-7. PubMed ID: 24518101
[TBL] [Abstract][Full Text] [Related]
6. Non FDG PET.
Nanni C; Fantini L; Nicolini S; Fanti S
Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
[TBL] [Abstract][Full Text] [Related]
7. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
8. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
9. Non-[18F]FDG PET in clinical oncology.
Groves AM; Win T; Haim SB; Ell PJ
Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
[TBL] [Abstract][Full Text] [Related]
10. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
Antunovic L; Rodari M; Rossi P; Chiti A
PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
[TBL] [Abstract][Full Text] [Related]
11. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
12. [Positron emission tomography and evaluation of response to targeted therapies].
Gauthier H
Bull Cancer; 2009 Nov; 96(11):1087-97. PubMed ID: 19875353
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
14. [The contribution of PET to radiation treatment planning].
Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
[TBL] [Abstract][Full Text] [Related]
15. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
16. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
[TBL] [Abstract][Full Text] [Related]
17. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
18. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
[TBL] [Abstract][Full Text] [Related]
19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
20. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]